Free Trial
NASDAQ:ICCC

ImmuCell (ICCC) Stock Price, News & Analysis

ImmuCell logo
$6.00 -0.37 (-5.81%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.04 +0.04 (+0.58%)
As of 08/1/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ImmuCell Stock (NASDAQ:ICCC)

Key Stats

Today's Range
$5.99
$6.35
50-Day Range
$6.14
$7.60
52-Week Range
$3.34
$7.60
Volume
20,428 shs
Average Volume
15,899 shs
Market Capitalization
$54.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmuCell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
2nd Percentile Overall Score

ICCC MarketRank™: 

ImmuCell scored higher than 2% of companies evaluated by MarketBeat, and ranked 919th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for ImmuCell.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmuCell is -85.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmuCell is -85.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ImmuCell has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ImmuCell's valuation and earnings.
  • Percentage of Shares Shorted

    0.33% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently increased by 38.13%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ImmuCell does not currently pay a dividend.

  • Dividend Growth

    ImmuCell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.33% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently increased by 38.13%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for ImmuCell this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmuCell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.60% of the stock of ImmuCell is held by insiders.

  • Percentage Held by Institutions

    Only 13.47% of the stock of ImmuCell is held by institutions.

  • Read more about ImmuCell's insider trading history.
Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

ICCC Stock News Headlines

ImmuCell Embarks on CEO Succession Planning Process
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
See More Headlines

ICCC Stock Analysis - Frequently Asked Questions

ImmuCell's stock was trading at $5.15 at the beginning of the year. Since then, ICCC stock has increased by 16.5% and is now trading at $6.00.

ImmuCell Corporation (NASDAQ:ICCC) announced its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported $0.16 earnings per share for the quarter. The biotechnology company had revenue of $8.07 million for the quarter. ImmuCell had a negative trailing twelve-month return on equity of 1.02% and a negative net margin of 1.00%.
Read the conference call transcript
.

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

Last Earnings
5/14/2025
Today
8/02/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ICCC
CIK
811641
Employees
70
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.16 million
Net Margins
-1.00%
Pretax Margin
-0.96%
Return on Equity
-1.02%
Return on Assets
-0.61%

Debt

Debt-to-Equity Ratio
0.30
Current Ratio
4.12
Quick Ratio
2.21

Sales & Book Value

Annual Sales
$26.49 million
Price / Sales
2.05
Cash Flow
$0.06 per share
Price / Cash Flow
99.07
Book Value
$3.09 per share
Price / Book
1.94

Miscellaneous

Outstanding Shares
9,040,000
Free Float
8,441,000
Market Cap
$54.24 million
Optionable
Not Optionable
Beta
0.30

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:ICCC) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners